New drug overcomes resistance in aggressive breast cancers
icr.ac.uk
icr.ac.uk
The drug development is going to be complicated. The drug doesn’t work well by itself, so getting the right combination dosing and schedule is crucial. It also only works in some tumours and there is a candidate biomarker, so a clinically meaningful assay has to be developed. There is also no idea about toxicity yet. Long road ahead.
I really don't understand the evolutionary/Darwinian spin. It doesn't make sense, it looks like a buzzword. They just (try to) kill all the cells that reproduce like other chemotherapy drugs.
Form the abstract: https://mct.aacrjournals.org/content/18/10/1696
> In in vivo pharmacodynamic experiments, BOS172722 potently inhibits the spindle assembly checkpoint induced by paclitaxel in human tumor xenograft models of TNBC, [....]
I think the key part is "spindle assembly checkpoint" https://en.wikipedia.org/wiki/Spindle_checkpoint